Apellis currently accepts requests for grants and giving support pertaining to the following therapeutic areas and patient communities:

• Paroxysmal Nocturnal Hemoglobinuria (PNH)
• Geographic Atrophy (GA)/Dry Macular Degeneration (AMD)
• Amyotrophic lateral sclerosis (ALS)
• Immune complex membranoproliferative glomerulonephritis (IC-MPGN) and C3 glomerulopathy (C3G)
• Cold Agglutinin Disease (CAD)
• Hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA)
• Patient organizations working in areas that overlap with our medicines and pipeline
• Other investigational science observed within Apellis’ pipeline (particularly for non-CME grants)

This list is evaluated and updated regularly. Apellis reserves the right to review or modify therapeutic areas of interest at any time without notice.